Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

  • Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively
     
  • Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularly aggressive form of the disease, in Japan each year1-2
     
  • Japan follows US approval earlier this year and demonstrates the company’s commitment to reimagining medicine for lung cancer …
/by

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients:

  • Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC),
  • Entresto® (sacubitril valsartan sodium hydrate) in chronic heart failure,
  • Mayzent® (siponimod fumaric acid …
/by

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

  • EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis
     
  • CHMP opinion based on two Phase III studies showing Cosentyx provides fast and strong skin clearance and significant improvement in quality of life1
     
  • Moderate-to-severe psoriasis affects more than 350,000 children worldwide2, with the physical and psychological burden disrupting important formative years3
     
  • Potential new indication reinforces Cosentyx …
/by

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

  • If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglobulin E (IgE) antibody specifically designed to target and block IgE, a key driver in the inflammatory pathway
     
  • Decision based on results from the Phase III POLYP 1 and 2 studies, in which omalizumab* significantly reduced the size of nasal polyps (defined by Nasal Polyp Score) and improved nasal congestion (defined by Nasal Congestion Score …
/by

Novartis Resolves Legacy FCPA Investigations

Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former subsidiaries will pay USD 233.9 million to the DOJ and USD 112.8 million to the SEC.

To resolve the DOJ investigation, Novartis Hellas S.A.C.I. has entered into a deferred prosecution agreement (“Novartis Hellas DPA …

/by

Novartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis

  • The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS
     
  • Canadian company AccessNow receives the first prize worth USD 250,000 for a mobile app and web platform that provides information about the accessibility status for people with disabilities of locations around the world, …
/by

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

    • 83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago
       
    • 86% of tech professionals agree: the healthcare and pharma industry’s “digital moment” has arrived
       
    • Healthcare and pharma more than twice as attractive as traditional careers in financial services, telecoms and manufacturing
       
    • Report includes insights from Microsoft, MIT and Benevolent AI on the powerful pairing of …
/by

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19

On Wednesday June 24, 2020, Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The report, which includes insights from Microsoft, MIT and Benevolent AI highlights:

  • 83% of tech professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago
  • 86% of tech professionals agree: the healthcare and pharma industry’s “digital moment” has arrived
  • Healthcare and …
/by

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
     
  • Novartis remains committed to ongoing research and development for COVID-19
     
  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

Basel, June 19, 2020 — Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made …

/by

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

 

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made

 

  • Novartis remains committed to ongoing research and development for COVID-19

 

  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

 

Basel, June 19, 2020 — Novartis has made the decision to stop and …

/by